Granted Patent
B2
US 12,565,655 · App. 19/216,307 · Granted Mar 3, 2026
Composition for regulating production of interfering ribonucleic acid
Assignee:
Wyvern Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The embodiments of the present disclosure relate to decreasing the bioavailability of Fms-like tyrosine kinase 3 (FLT3) by providing a composition that comprises a recombinant plasmid with one or more sequences of miRNA. When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of FLT3.
Claims (2)
1 . A composition that comprises a recombinant plasmid (RP) comprising a sequence of nucleotides that is SEQ ID NO: 16.
2 . The composition of claim 1 , wherein the RP is encapsulated in a protein coat, a lipid vesicle, or any combination thereof.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 20, 2025
From: THOPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072073/0434 →
Continuity (3)
References Cited (46)
CA 2721333A1
· 2009
[cited by applicant]
Kenji and Mizukami < star-protocols.cell.com/protocols/3185 >, Dec. 15, 2023, 17 pages, accessed on Sep. 9, 20225 (Year: 2023).
[cited by examiner]
Lundstrom K., Viruses. Mar. 7, 2023;15(3):698 (Year: 2023).
[cited by examiner]
FLT3 Sequence Genbank revision history Nov. 2023 , 14 pages. Retrieved from the United States NCBI webpage on the internet <https://www.ncbi.nlm.nih.gov> [retrieved on Feb. 11, 2025]. (Year: 2023).
[cited by examiner]
Wallace JA et al., Blood, Apr. 21, 2017;129(23):3074-3086 (Year: 2017).
[cited by examiner]
Ying et al. 2008. Mol. Biotechnol. 38:257-268 (Year: 2008).
[cited by examiner]
Lam et al. 2015. Molec. Ther. Nuc. Ac. 4:e252 (Year: 2015).
[cited by examiner]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112.
[cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848.
[cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166.
[cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579.
[cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016).
[cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023).
[cited by applicant]
GenBank EGFR Sequence (2023).
[cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010).
[cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506.
[cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253.
[cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494.
[cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016.
[cited by applicant]
NCBI search results for SEQ ID No. 5 (2024).
[cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023).
[cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024).
[cited by applicant]
GenBank FLT3 Sequence (2024).
[cited by applicant]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402.
[cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228.
[cited by applicant]
GenBank EGF Sequence (2023).
[cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675.
[cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378.
[cited by applicant]
Pagliuca (et al. 2013. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32:4806-4813) (Year: 2013).
[cited by applicant]
Fattore (et al. 2016. miR-579-3p controls melanoma progression and resistance to target therapy. PNAS 113 [34]:E5005-E5013) ( Year: 2016).
[cited by applicant]
Origene (2024. Product datasheet for SC207797 B Raf [BRAF] [NM_004333] Human 3′ UTR Clone. Rockville, MD: Origene) (Year:2024).
[cited by applicant]
NCBI (
[cited by applicant]
MiRbase (2025. “miR-143” and “miR-145”, and “miR-579-3p”. Available online at miRbase.org. Accessed on May 16, 2025) (Year: 2025).
[cited by applicant]
[cited by applicant]
Zhang et al. Drug Design, Development and Therapy, Published Feb. 22, 2021, pp. 721-733. (Year: 2021).
[cited by applicant]